Jennison Associates’s NewAmsterdam Pharma NAMS Stock Holding History
Bought
Maintained
Sold
Other funds holding NAMS
DFO
Jennison Associates's NAMS Position: Q3 2026 in Review
Jennison Associates reduced its NewAmsterdam Pharma (NAMS) stake by 1.2% in Q3 2026, selling an estimated $683K and leaving 2,077,595 shares worth $50.5M. The position accounts for 0.03% of the portfolio, ranked #231.
Jennison Associates first reported a position in NAMS in Q1 2024 and has held it in 11 quarters since. The position peaked at $122M in Q4 2025. 183 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.
- Jennison Associates held 2,077,595 shares of NewAmsterdam Pharma worth $50.5M as of Q3 2026.
- Jennison Associates sold 24,691 NewAmsterdam Pharma shares in Q3 2026, an estimated $683K.
- NewAmsterdam Pharma made up 0.03% of Jennison Associates's portfolio in Q3 2026, its #231 holding.
- Jennison Associates first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 11 quarters since.
- Jennison Associates's NewAmsterdam Pharma position peaked at $122M in Q4 2025.
- 183 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.
Based on Jennison Associates's 13F filing for Q3 2026, filed 16 Nov 2026.